Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weintraub, K. Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med 22, 8–10 (2016). https://doi.org/10.1038/nm0116-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0116-8
- Springer Nature America, Inc.
This article is cited by
-
Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
Clinical and Translational Oncology (2022)
-
Endogenous retroviruses in the origins and treatment of cancer
Genome Biology (2021)
-
Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
BMC Immunology (2020)
-
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Targeted Oncology (2020)
-
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
Journal of Experimental & Clinical Cancer Research (2019)